Galactose-modified duocarmycin prodrugs as senolytics
A. Guerrero, R. Guiho, N. Herranz, A. Uren, D. Withers, J. P. Martinez-Barbera, L. Tietze, J. Gil
This study develops galactose-modified duocarmycin prodrugs that selectively kill senescent cells by targeting lysosomal β-galactosidase, showing therapeutic potential for age-related diseases.
bioRxiv · Aug 24, 2019Cell Biology